Healthcare news

News for Alberta’s health workforce

Short briefs on what is changing in healthcare in Alberta and across Canada, collected from official bodies and news outlets, each linked to its original source.

Check the original source before acting.

Public healthCanada

Mylan fluconazole 100 mg tablets face supply disruption until April 13

Mylan Pharmaceuticals reports its Mylan-Fluconazole 100 mg tablet (DIN 02245293) is in an actual shortage that began Oct 13, 2026 and is expected to run until Apr 13, 2027, after a disruption in manufacturing.

Fluconazole is a widely used antifungal — pharmacies should check stock and alternatives while the shortage runs.

Public healthCanada

Sandoz discontinues 50 mg diclofenac potassium tablets effective September 8

Sandoz Canada reports its Sandoz Diclofenac Rapide (diclofenac potassium) 50 mg tablet (DIN 02261774) is in an actual shortage that began Sep 8, 2026, because the product is to be discontinued. No expected end date is given.

Diclofenac is a widely used pain and inflammation drug — prescribers and pharmacies should switch patients to another diclofenac product before this one is discontinued.

Public healthCanada

BGP Pharma reports Caduet 10 mg 10 mg tablet shortage starting December

BGP Pharma reports its Caduet (amlodipine / atorvastatin) 10 mg / 10 mg tablet (DIN 02273284) faces an anticipated shortage from Dec 15, 2026 to Jan 12, 2027, after a disruption in manufacturing.

Caduet combines a blood-pressure drug and a cholesterol drug in one tablet — patients may need the two drugs separately during the gap.

Public healthCanada

BGP Pharma reports Zoloft 25 mg shortage lasting until January 5

BGP Pharma reports its Zoloft (sertraline) 25 mg capsule (DIN 02132702) is in an actual shortage that began Oct 9, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Sertraline is one of the most commonly prescribed antidepressants — pharmacies should check stock and alternatives while the shortage runs.

Public healthCanada

BGP Pharma reports manufacturing shortage of 40 mg Zeldox capsules

BGP Pharma reports its Zeldox (ziprasidone) 40 mg capsule (DIN 02298600) is in an actual shortage that began Oct 6, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Ziprasidone is used to treat schizophrenia and bipolar disorder — care teams should confirm supply and alternatives while the shortage runs.

Public healthCanada

BGP Pharma reports manufacturing disruption causing shortage of 2 mg Mavik capsules

BGP Pharma reports its Mavik (trandolapril) 2 mg capsule (DIN 02231460) is in an actual shortage that began Sep 23, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Trandolapril is a blood-pressure drug — pharmacies should check stock and alternatives while the shortage runs.

AlertPublic healthCanada

Ebola outbreak reaches 9800 cases as regional travel restrictions tighten

The Ebola outbreak in the Democratic Republic of Congo has passed 9,800 cases and 4,700 deaths since May, the deadliest in the country's history. A nurse was killed and a health worker severely injured on Saturday in Bafwasende while responding to an Ebola alert. A Ugandan-born Swiss woman, Nigeria's first case, was flown from Abuja to Switzerland on Monday; she is stable in Geneva, her husband is in isolation in Zurich, and Nigeria now has no cases. Kenya has nine cases, two fatal; Uganda now requires citizens returning from the DRC to quarantine 21 days at their own expense.

The deadliest Ebola outbreak in DRC history is now spreading across borders — frontline workers should know the travel and quarantine rules as cases reach Nigeria, Kenya and Uganda.

Public healthCanada

BGP Pharma reports Zoloft 100 mg shortage lasting until January 5

BGP Pharma reports its Zoloft (sertraline) 100 mg capsule (DIN 01962779) is in an actual shortage that began Sep 25, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Sertraline is one of the most commonly prescribed antidepressants — pharmacies should check stock and alternatives while the shortage runs.

Due in 4 daysPublic healthCanada

BGP Pharma reports one-week supply shortage for 100 mcg Synthroid tablets

BGP Pharma reports its Synthroid (levothyroxine sodium) 100 mcg tablet (DIN 02172100) faces an anticipated shortage starting Oct 26, 2026 and expected to end Nov 3, 2026, driven by increased demand.

Levothyroxine is one of the most commonly prescribed drugs in Canada — even a one-week gap matters, so pharmacies should check stock now.

Due in 2 daysHealth policyAlberta

Alberta optometrists to perform minor eye surgeries starting November 1 2026

Starting November 1, 2026, Alberta optometrists with specialized training may perform minor surgical and laser procedures, including stye treatments and skin lesion removal. These regulatory changes aim to reduce wait times and travel for patients. Ophthalmologists will focus on complex cases as optometrists take on these additional community-based services under new oversight standards.

If you are an ophthalmologist, you may see fewer referrals for minor procedures as qualified optometrists begin providing these services in their own clinics.

RecallTech & trendsCanada

Abbott issues security update for FreeStyle Libre 3 mobile app

Abbott has released a mandatory security update for the FreeStyle Libre 3 app on Android and iOS. A previous patch to address a vulnerability caused a defect that may lead to prolonged communication loss between the app and the sensor. Users must update to version 3.6.10 immediately to resolve this issue.

If you assist patients using this system, ensure they update their app to version 3.6.10 to prevent sensor connection failures.

RecallTech & trendsCanada

Medtronic updates instructions for Abre venous stent system deployment

Medtronic has issued a recall to update the instructions for use for the Abre venous self-expanding stent system. The update provides a validated manual deployment method to address rare instances of partial stent deployment. No product returns or disposals are required.

If you use this device, review the new manual deployment instructions provided by the manufacturer to manage potential partial stent deployment.

RecallTech & trendsCanada

Beckman Coulter clinical analyzers may reset calculated test rules after software updates

Beckman Coulter reports that DxC 500i and DxC 500 AU clinical chemistry analyzers may revert custom calculated rules to default settings following software or parameter package upgrades. Operators who have modified these 25 predefined rules must verify settings after any system updates.

If you use these analyzers, check your calculated test rules after any software or parameter package updates to ensure they remain correctly configured.

Due in 16 daysPublic healthCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Due in 16 daysPublic healthCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Due in 35 daysPublic healthCanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Due in 14 daysPublic healthCanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Due in 7 daysPublic healthCanada

Sandoz reports supply shortage of sufentanil injection through early November

Sandoz Canada reports its sufentanil citrate injection 50 mcg (DIN 02244147), for epidural or intravenous use, is in an actual shortage that began Oct 13, 2026 and is expected to run until Nov 6, 2026, driven by increased demand.

Sufentanil is used in anaesthesia and pain care — hospitals should confirm supply and alternatives while the shortage runs.

Due todayPublic healthCanada

Piperacillin-tazobactam injection from Sandoz in short supply until Oct 30 after shipping delay

Sandoz Canada reports its piperacillin and tazobactam powder for injection (DIN 02521539) is in an actual shortage that began Oct 19, 2026 and is expected to run until Oct 30, 2026, caused by a delay in shipping.

Piperacillin-tazobactam is a widely used IV antibiotic — hospitals should check stock and alternatives while the shortage runs.

Public healthCanada

Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026

Baxter Corporation reports its Procytox (cyclophosphamide) 200 mg powder for intravenous solution (DIN 02241797) will be discontinued on Dec 31, 2026, for business reasons. The discontinuation decision will not be reversed.

Cyclophosphamide is a standard chemotherapy drug — cancer care teams should plan the switch to another strength or product before Dec 31.

Health policyCanada

High cost of new pancreatic cancer drug limits patient access in Manitoba

Daraxonrasib (Rasonque), a pancreatic cancer pill approved by the U.S. FDA in August but not yet in Canada, costs about C$90,000 a month - Vancouver patient James Howard pays about US$63,000 a month for three daily doses. Its launch price is US$480,000 (C$675,000) a year. Trials showed it halted or reversed tumour growth in nearly a third of patients, versus about 10% on chemotherapy, and lifted survival from under 7 months to about 13. Oncologists say the price puts a life-extending drug out of reach; the maker says it reflects therapeutic advance and supports innovation.

CancerCare Manitoba oncologist Dr. Ralph Wong says patients in his practice are crying because they cannot access this drug, which is not yet approved in Canada - a stark example of how U.S. drug pricing leaves Canadians paying out of pocket or going without.

News source: CBC News (opens in a new tab)

Public healthCanada

Elective egg freezing cycles see sharp increase among Canadians

Egg-freezing retrievals in Canada rose from 217 cycles in 2013 to 2,663 in 2025, with over 22,000 eggs banked last year, up from 775, per the Canadian Fertility and Andrology Society. Doctors cite high living costs, career ambitions, later parenthood and a lack of a partner. A cycle typically costs $11,000-$16,000 with medication and a year of storage, and public funding does not cover elective freezing. Freezing 20-25 eggs in the early 30s gives about a 75% chance of a baby, but success is never guaranteed - and only about 11% of people who froze eggs have gone back to thaw them.

Elective fertility preservation is surging while staying out of reach for many: a cycle costs $11,000-$16,000 with no public funding. Anyone considering it should know the costs, the odds, and that a fertility-clinic consultation is the recommended first step.

News source: CBC News (opens in a new tab)

Health policyAlberta

Alberta expands hospital capacity and launches triage program for respiratory season

Alberta has increased acute care capacity to over 9,000 spaces, including 221 permanent beds and 194 temporary beds. The province also launched a Provincial Integrated Operations Centre to coordinate resources and a Triage Liaison Physician program to place doctors in emergency waiting areas. Additionally, hospitals are implementing automated daily staffing reports to improve resource management.

You may see triage physicians in emergency waiting areas and use new automated staffing reporting tools to help manage seasonal patient surges.

Public healthCanada

Prince Edward Island launches provincial alcohol strategy to address health care impacts

P.E.I. released a 16-recommendation alcohol strategy after five years of planning, aiming to reduce drinking rather than ban it. Measures include screening for high-risk drinking at medical appointments, youth programs, pricing by alcohol content, and putting 3 per cent of net alcohol profits into community and harm-reduction work. Alcohol causes about 7,000 ER visits and hospitalizations a year on the Island, and impaired driving rates are nearly three times the national average.

The strategy links alcohol policy directly to health care: screening in clinics, and a share of liquor profits funding harm reduction.

News source: CBC News (opens in a new tab)

Health policyCanada

Low awareness limits uptake of federal disability savings plans among eligible Canadians

Only about 34 per cent of Canadians eligible for the Registered Disability Savings Plan have opened one, a 2024 Statistics Canada investigation found, versus roughly 68 per cent uptake for TFSAs and RRSPs. The plan offers up to $70,000 in federal grants and $20,000 in bonds, but take-up is held back by low awareness, few providers, and a 16-page clinician questionnaire needed to qualify for the Disability Tax Credit.

Frontline workers may be the first to tell eligible clients about a plan worth up to $90,000 in federal help that most never hear about.

News source: CBC News (opens in a new tab)

Services & workforceCanada

Fatality inquiry examines emergency department overcrowding and patient capacity issues in Edmonton

A fatality inquiry heard that Prashant Sreekumar, 44, died on Dec. 22, 2025 after waiting about eight hours in the Grey Nuns emergency department in Edmonton for chest pain. A doctor testified the hospital's five general medicine units have run above capacity since at least 2024, with occupancy around 101 per cent in 2025, and that 20 to 30 per cent of beds hold patients who no longer need hospital care. The inquiry resumes in December.

The testimony puts numbers to ER overcrowding: more patients than beds, and a fifth to a third of beds taken by patients awaiting placement elsewhere.

News source: CBC News (opens in a new tab)